Overview: Leishmania IgG TestIntroduction: The Leishmania IgG Test detects Leishmania IgG to diagnose kala-azar, causing fever or weight loss. Aligned with 2023 WHO guidelines, it uses immunoassay for high specificity, supporting parasite screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in parasitology for patients with suspected visceral leishmaniasis.
Other Names: Leishmania IgG Assay, Kala-Azar IgG Test.
FDA Status: Laboratory-developed test (LDT), meeting parasitology standards for diagnostic accuracy.
Historical Milestone: Leishmania IgG testing began in the 1980s with kala-azar research. Immunoassay methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects Leishmania IgG to diagnose kala-azar, guides treatment, and evaluates patients with fever or weight loss.
Test Parameters: 1. Leishmania IgG Antibodies
Pretest Condition: No fasting required. Collect serum or saliva. Report history of fever, weight loss, or spleen enlargement.
Specimen: Serum (SST, 2-5 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fever, weight loss, spleen enlargement, or travel history to leishmaniasis-endemic areas. Include current medications, especially antiparasitics.
Consent: Written consent required, detailing the tests purpose, kala-azar implications, and risks of blood or saliva collection.
Procedural Considerations: Uses immunoassay to detect Leishmania IgG in serum or saliva. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for kala-azar diagnosis.
Factors Affecting Result Accuracy: Hemolysis, lipemia, or improper sample storage can affect results. Early infection may yield false negatives.
Clinical Significance: Positive Leishmania IgG confirms kala-azar, guiding antiparasitic therapy (e.g., amphotericin B). Negative results may require PCR or further testing.
Specialist Consultation: Consult an infectious disease specialist for result interpretation and treatment planning.
Additional Supporting Tests: Leishmania RK-39 test, bone marrow biopsy, or PCR to confirm kala-azar diagnosis.
Test Limitations: May detect past exposure; clinical correlation is needed. Cross-reactivity with other parasites may occur.
References: WHO Leishmaniasis Guidelines, 2023; The Lancet Infectious Diseases, Alvar J, 2022.
